Lateral Flow Tests Detect Most Infectious COVID-19 Cases, Reveals New Research
By LabMedica International staff writers Posted on 28 Jan 2021 |

Illustration
Lateral flow devices can detect most infectious COVID-19 cases and could allow a safer relaxation of the current lockdown, according to a new study.
Researchers from the University of Oxford (Oxford, UK), working with Public Health England and NHS Test and Trace, have used Test and Trace data to find out why some individuals pass COVID-19 on to their contacts more easily than others, and if lateral flow tests are sufficient in detecting those who are most infectious. Using information from over a quarter of a million people who have participated in the UK government’s Test and Trace program, the scientists found that in all groups, the more virus detected in the nose and throat (known as ‘viral load’), the more infectious the individual is. This is the first time this has been confirmed in a large-scale study and explains part of why some people pass COVID-19 on and others do not. Overall, only six in 100 contacts of infected cases went on to get infected themselves.
Understanding why some individuals with COVID-19 are more infectious than others has been a key piece of information missing from creating a more effective testing system. Since those with higher viral loads are more likely to pass the infection on to others, these infected individuals are the most important to detect, so they can be isolated, thus, reducing onward transmission. COVID-19 tests that are less sensitive than the standard PCR but, easier to make widely available, such as lateral flow tests, could be a good solution to ensuring those who are highly infectious are able to know they need to isolate more quickly and could allow an easing of lockdown restrictions. They would also allow more people to be tested yielding immediate results, including those who do not have symptoms and people at increased risk of testing positive, for example, because of their work or having been a contact themselves.
Although lateral flow tests are a rapid and relatively cheap way to detect COVID-19, their role in detecting actively infectious people has been controversial. While lateral flow tests do not detect as many cases as the standard PCR test, there has been much debate on whether they are ‘good enough’ to catch most infectious cases of COVID-19. It was already known that lateral flow tests are more accurate the more virus that is present. Because this research has shown that the same people who are detected best by lateral flow kits, with high viral loads, are also the most infectious, this means that lateral flow tests can detect most people who would otherwise go on to infect someone else. In the current research, modeling has found that they would be effective at detecting up to 90% of the infections that the individuals then passed on to their contacts.
“Lateral flow tests have been very popular with staff at our hospitals in Oxford, with over 60,000 tests done since November. We’ve been able to detect asymptomatic infected staff who would not have been otherwise diagnosed, protecting patients and staff. The tests can be done at home before coming to work with a result available within 30 minutes,” said Tim Peto, Professor of Medicine at the University of Oxford and senior author on the study. “We know that lateral flow tests are not perfect, but that doesn’t stop them being a game changer for helping to detect large numbers of infectious cases sufficiently rapidly to prevent further onward spread.”
Related Links:
University of Oxford
Researchers from the University of Oxford (Oxford, UK), working with Public Health England and NHS Test and Trace, have used Test and Trace data to find out why some individuals pass COVID-19 on to their contacts more easily than others, and if lateral flow tests are sufficient in detecting those who are most infectious. Using information from over a quarter of a million people who have participated in the UK government’s Test and Trace program, the scientists found that in all groups, the more virus detected in the nose and throat (known as ‘viral load’), the more infectious the individual is. This is the first time this has been confirmed in a large-scale study and explains part of why some people pass COVID-19 on and others do not. Overall, only six in 100 contacts of infected cases went on to get infected themselves.
Understanding why some individuals with COVID-19 are more infectious than others has been a key piece of information missing from creating a more effective testing system. Since those with higher viral loads are more likely to pass the infection on to others, these infected individuals are the most important to detect, so they can be isolated, thus, reducing onward transmission. COVID-19 tests that are less sensitive than the standard PCR but, easier to make widely available, such as lateral flow tests, could be a good solution to ensuring those who are highly infectious are able to know they need to isolate more quickly and could allow an easing of lockdown restrictions. They would also allow more people to be tested yielding immediate results, including those who do not have symptoms and people at increased risk of testing positive, for example, because of their work or having been a contact themselves.
Although lateral flow tests are a rapid and relatively cheap way to detect COVID-19, their role in detecting actively infectious people has been controversial. While lateral flow tests do not detect as many cases as the standard PCR test, there has been much debate on whether they are ‘good enough’ to catch most infectious cases of COVID-19. It was already known that lateral flow tests are more accurate the more virus that is present. Because this research has shown that the same people who are detected best by lateral flow kits, with high viral loads, are also the most infectious, this means that lateral flow tests can detect most people who would otherwise go on to infect someone else. In the current research, modeling has found that they would be effective at detecting up to 90% of the infections that the individuals then passed on to their contacts.
“Lateral flow tests have been very popular with staff at our hospitals in Oxford, with over 60,000 tests done since November. We’ve been able to detect asymptomatic infected staff who would not have been otherwise diagnosed, protecting patients and staff. The tests can be done at home before coming to work with a result available within 30 minutes,” said Tim Peto, Professor of Medicine at the University of Oxford and senior author on the study. “We know that lateral flow tests are not perfect, but that doesn’t stop them being a game changer for helping to detect large numbers of infectious cases sufficiently rapidly to prevent further onward spread.”
Related Links:
University of Oxford
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Blood Biomarker Test Could Detect Genetic Predisposition to Alzheimer’s
New medications for Alzheimer’s disease, the most common form of dementia, are now becoming available. These treatments, known as “amyloid antibodies,” work by promoting the removal of small deposits from... Read more
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more
New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
"Liquid biopsy" technology, which relies on blood tests for early cancer detection and monitoring cancer burden in patients, has the potential to transform cancer care. However, detecting the mutational... Read more
"Metal Detector" Algorithm Hunts Down Vulnerable Tumors
Scientists have developed an algorithm capable of functioning as a "metal detector" to identify vulnerable tumors, marking a significant advancement in personalized cancer treatment. This breakthrough... Read more
Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
Pancreatic cancer is often asymptomatic in its early stages, making it difficult to detect until it has progressed. Consequently, only 15% of pancreatic cancers are diagnosed early enough to allow for... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more